Monopar Therapeutics Inc. (MNPR)Healthcare | Biotechnology | Wilmette, United States | NasdaqCM
71.80 USD
-1.30
(-1.778%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 71.80 |
Hot Take ↕ | Oct. 10, 2026, 10:07 a.m. EDT
The immediate outlook is severely clouded by aggressive selling pressure; the stock has tumbled from $96.63 to $78.96 over the last two weeks, erasing nearly 20% of its value in mere days. This sharp decline suggests a lack of near-term catalysts to arrest the momentum, despite the broader market's recent recovery. While the long-term picture tells a different story—driven by a spectacular 1,598% surge in the latest fiscal year and a massive 234% gain over the five-year window—the current price action indicates the market is currently pricing in significant uncertainty regarding the company's ability to sustain this growth or manage its cash burn. The disconnect between the soaring long-term trajectory and the precipitous short-term drop creates a volatile environment where the immediate trend is decisively downward, overshadowing the potential for a rebound until clearer signs of stabilization emerge. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.078564 |
| MSTL | 0.084236 |
| AutoTheta | 0.200573 |
| AutoARIMA | 0.303890 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 1.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.57 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.157 |
| Market Cap | 481,933,984 |
| Forward P/E | -37.48 |
| Beta | 1.51 |
| Website | https://www.monopartx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.11458331 |
| Address1 | 1,000 Skokie Boulevard |
| Address2 | Suite 350 |
| All Time High | 240.0 |
| All Time Low | 1.37 |
| Ask | 75.0 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 160,520 |
| Average Daily Volume3 Month | 206,973 |
| Average Volume | 206,973 |
| Average Volume10Days | 160,520 |
| Beta | 1.513 |
| Bid | 73.9 |
| Bid Size | 5 |
| Board Risk | 10 |
| Book Value | 19.495 |
| City | Wilmette |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 71.8 |
| Current Ratio | 33.556 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 73.28 |
| Day Low | 70.05 |
| Debt To Equity | 0.157 |
| Display Name | Monopar Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,561,200 |
| Earnings Timestamp End | 1,794,510,000 |
| Earnings Timestamp Start | 1,794,510,000 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 347,840,640 |
| Eps Current Year | -3.0405 |
| Eps Forward | -1.91575 |
| Eps Trailing Twelve Months | -2.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 101.8321 |
| Fifty Day Average Change | -30.032097 |
| Fifty Day Average Change Percent | -0.2949178 |
| Fifty Two Week Change Percent | -11.458331 |
| Fifty Two Week High | 124.82 |
| Fifty Two Week High Change | -53.019997 |
| Fifty Two Week High Change Percent | -0.42477164 |
| Fifty Two Week Low | 50.07 |
| Fifty Two Week Low Change | 21.730003 |
| Fifty Two Week Low Change Percent | 0.43399248 |
| Fifty Two Week Range | 50.07 - 124.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,576,765,800,000 |
| Float Shares | 4,467,219 |
| Forward Eps | -1.91575 |
| Forward P E | -37.478794 |
| Free Cashflow | -6,098,616 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Fullday Change | -1.2999954 |
| Fullday Change Percent | -1.7783796 |
| Fullday Price | 71.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.23472 |
| Held Percent Institutions | 0.94908 |
| Implied Shares Outstanding | 6,712,172 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,507,200 |
| Last Split Factor | 1:5 |
| Long Business Summary | Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois. |
| Long Name | Monopar Therapeutics Inc. |
| Market | us_market |
| Market Cap | 481,933,984 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_304391755 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -17,844,746 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 597,584,673 |
| Number Of Analyst Opinions | 12 |
| Open | 73.2 |
| Operating Cashflow | -12,181,947 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Phone | 847 388 0349 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 71.8 |
| Post Market Time | 1,792,094,436 |
| Previous Close | 73.1 |
| Price Eps Current Year | -23.614538 |
| Price Hint | 2 |
| Price To Book | 3.6829956 |
| Profit Margins | 0.0 |
| Quick Ratio | 33.441 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.3 |
| Regular Market Change Percent | -1.77838 |
| Regular Market Day High | 73.28 |
| Regular Market Day Low | 70.05 |
| Regular Market Day Range | 70.05 - 73.28 |
| Regular Market Open | 73.2 |
| Regular Market Previous Close | 73.1 |
| Regular Market Price | 71.8 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 139,378 |
| Return On Assets | -0.1464 |
| Return On Equity | -0.19496 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 6,712,172 |
| Shares Percent Shares Out | 0.1618 |
| Shares Short | 1,086,279 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 852,425 |
| Short Name | Monopar Therapeutics Inc. |
| Short Percent Of Float | 0.2369 |
| Short Ratio | 7.15 |
| Source Interval | 15 |
| State | IL |
| Symbol | MNPR |
| Target High Price | 145.0 |
| Target Low Price | 119.0 |
| Target Mean Price | 129.91667 |
| Target Median Price | 130.0 |
| Total Cash | 134,298,976 |
| Total Cash Per Share | 20.008 |
| Total Debt | 205,663 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 76.8235 |
| Two Hundred Day Average Change | -5.0234985 |
| Two Hundred Day Average Change Percent | -0.065390125 |
| Type Disp | Equity |
| Volume | 139,378 |
| Website | https://www.monopartx.com |
| Zip | 60,091 |